021-51111890
购物车（）
sales@molnova.cn
Eptifibatide acetate
CAS No. 881997-86-0
Eptifibatide acetate ( —— )
产品货号. M19934 CAS No. 881997-86-0
Eptifibatide an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class is a cyclic heptapeptide constructed from 6 amino acids and a mercaptopropionyl residue.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥405 | 有现货 |
|
| 10MG | ￥446 | 有现货 |
|
| 25MG | ￥729 | 有现货 |
|
| 50MG | ￥1166 | 有现货 |
|
| 100MG | ￥1831 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Eptifibatide acetate
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Eptifibatide an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class is a cyclic heptapeptide constructed from 6 amino acids and a mercaptopropionyl residue.
-
产品描述Eptifibatide an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class is a cyclic heptapeptide constructed from 6 amino acids and a mercaptopropionyl residue.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Others
-
研究领域Cardiovascular Disease
-
适应症Stroke
化学信息
-
CAS Number881997-86-0
-
分子量——
-
分子式C35H49N11O9S2·xC2H4O2
-
纯度>98% (HPLC)
-
溶解度DMSO:10 mM
-
SMILESCC(=O)O.NC(=O)[C@@H]3CSSCCC(=O)N[C@@H](CCCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc2cnc1ccccc12)C(=O)N4CCC[C@H]4C(=O)N3
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Amoroso G. et al. Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease. J Cardiovasc Pharmacol 2001. 38(4): p. 633-41.
产品手册
关联产品
-
Methyl nomilinate
Methyl nomilinate from citrus can modulate cell cycle regulators to induce cytotoxicity in human colon cancer (SW480) cells in vitro.
-
Epidermal growth fac...
The epidermal growth factor receptor is the cell-surface receptor for members of the epidermal growth factor family of extracellular protein ligands.
-
R-IMPP
R-IMPP is an inhibitor of PCSK9 translation. R-IMPP stimulates uptake of LDL-C in hepatoma cells by increasing LDL-R levels, without altering levels of secreted transferrin.
